Results 101 to 110 of about 152,178 (350)

Antibody‐Empowered Nanomedicine for Precise Biomedical Applications

Advanced Science, EarlyView.
This review explores strategies for functionalizing nanoparticles with antibodies to construct antibody‐empowered nanomedicine. It discusses the classification of these nanomedicines based on antibody structure, with a specific focus on their biomedical applications in diagnostics, bioimaging, and therapeutics for various diseases.
Chen Chen, Xinglin Chen, Zhenhao Gao, Meng Sun, Yaozong Yu, Fang Lv, Qiujun Wang, Jinfeng Zhang   +7 more
wiley   +1 more source

Clinical and molecular characterization of HER2 amplified-pancreatic cancer [PDF]

, 2013
<p>Background: Pancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid improvements in outcome ...
Biankin, A.V., Chang, D.K., Chantrill, L., Chin, V., Chou, A., Cowley, M.J., Gill, A.J., Goldstein, D., Grimmond, S.M., Humphris, J., Johns, A.L., Kassahn, K.S., Mead, R., Miller, D.K., Morey, A.L., Musgrove, E.A., Nagrial, A.M., Nones, K., Pajic, M., Patch, A.M., Pearson, J.V., Pinese, M., Rooman, I., Samra, J.S., Toon, C.W., Waddell, N., Wasan, H., Wu, J.   +27 more
core   +3 more sources

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. [PDF]

, 2017
BackgroundTopoisomerase I (TOPO1) and topoisomerase IIα (TOP2A) are specific targets of multiple chemotherapy drugs. Increased expression of TOPO1 protein and amplification of the TOP2A gene have been associated with treatment response in colorectal and ...
Arguello, David, Gatalica, Zoran, Heestand, Gregory M, Kurzrock, Razelle, Schwaederle, Maria   +4 more
core   +1 more source

Precision oncology: the intention-to-treat analysis fallacy. [PDF]

, 2020
It has recently been suggested that precision oncology studies should be reanalysed using the intention-to-treat (ITT) methodology developed for randomized controlled clinical trials.
Kato, Shumei, Kurzrock, Razelle, Okamura, Ryosuke, Sicklick, Jason K   +3 more
core   +1 more source

Dynamischer Austausch von Bindemolekülen steigert die Effizienz der Proteinmarkierung in DNA‐PAINT um das bis zu 15‐Fache

Angewandte Chemie, EarlyView.
Der dynamische Austausch von Bindemolekülen (Dynamic Binder Exchange; DyBE) nutzt transiente Binde–Zielprotein‐Interaktionen, um die Markierungseffizienz in der superauflösenden Mikroskopie um das 15‐Fache zu steigern. DyBE kartiert die Organisation von Rezeptor‐Tyrosinkinasen (RTKs), einschließlich HER2‐Homodimere und EGFR–HER2‐Heterodimere, auf der ...
Clemens Steinek, Isabelle Pachmayr, Sebastian Strauss, Monique Honsa, Jisoo Kwon, Ralf Jungmann   +5 more
wiley   +1 more source

Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab

Breast Cancer: Basic and Clinical Research, 2018
Purpose: Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 (anti-HER2) antibody delivered intravenously, has revolutionized the treatment of patients with breast cancer overexpressing HER2 protein.
John Syrios, Evelina Pappa, Nikolaos Volakakis, Anastasios Grivas, John Alafis, Sofia Manioudaki, Vasiliki Tzouda, Athanasios Korogiannos, Cleopatra Rapti, Nektarios Koufopoulos, Adamantia Nikolaidou, Eleftheria Kanavou, Athanasios Alexopoulos, Anna Koumarianou   +13 more
doaj   +1 more source

Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report

BMC Cancer, 2017
Background Trastuzumab-related cardiotoxicity has been reported in patients receiving trastuzumab concurrently with other agents, especially with anthracyclines. Cardiac function damage is generally rare, precox and mild with trastuzumab alone.
Santino Minichillo, Ilaria Gallelli, Elena Barbieri, Marta Cubelli, Daniela Rubino, Sara Quercia, Massimo Dall’Olio, Claudio Rapezzi, Claudio Zamagni   +8 more
doaj   +1 more source

A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan

Breast, 2020
Objective: Treatment options for HER-2-positive metastatic breast cancer (mBC) patients have expanded markedly since trastuzumab approval in 1998. Several other regimens are now available, including pertuzumab plus trastuzumab plus docetaxel, T-DM1 ...
Vakaramoko Diaby, Hussain Alqhtani, Sascha van Boemmel-Wegmann, Ching-Yu Wang, Askal Ayalew Ali, Rajesh Balkrishnan, Yu Ko, Sofia Palacio, Gilberto de Lima Lopes   +8 more
doaj   +1 more source

Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA

Drugs - Real World Outcomes, 2023
Background Trastuzumab in combination with chemotherapy is the standard first-line (1L) treatment for HER2+ metastatic gastric cancer (mGC) in the USA.
Afsaneh Barzi, Feng Lin, Jinlin Song, Clara Lam, Xiaoyu Nie, Ahmed Noman, Winghan J. Kwong   +6 more
doaj   +1 more source

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: A phase 1 dose-escalation study [PDF]

, 2018
BackgroundThis phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated antibody-liposomal doxorubicin conjugate, in HER2-positive locally advanced/metastatic breast cancer.MethodsPatients were enrolled in four cohorts: MM-302 ...
Adiwijaya, Bambang S, Campbell, Karen, Geretti, Elena, Hendriks, Bart S, Krop, Ian E, LoRusso, Patricia, Ma, Cynthia, Miller, Kathy D, Molnár, István, Moyo, Victor, Munster, Pamela, Reynolds, Joseph, Shields, Anthony F, Siegel, Barry A, Wickham, Thomas J   +14 more
core   +2 more sources